P2Y12 INHIBITORS


Acronyms and Definitions



 DRUGS IN CLASS

Thienopyridines
Other

 MECHANISM OF ACTION

Platelet Activation


 EFFECTIVENESS


Acute heart attack



Secondary heart attack prevention


Primary Stroke Prevention
Secondary Stroke Prevention



Atrial Fibrillation



 SIDE EFFECTS

Clopidogrel (Plavix®)

Prasugrel (Effient®)

Ticagrelor (Brilinta®)

Ticlopidine (Ticlid®)


 STOPPING BEFORE PROCEDURES



 PRECAUTIONS

Kidney disease

Liver disease

History of stroke or TIA

Geriatric (prasugrel)

Low body weight (prasugrel)


 DRUG INTERACTIONS

NOTE: Drug interactions presented here are NOT all-inclusive. Other interactions may exist. The interactions presented here are meant to encompass commonly prescribed medications and/or interactions that are well-documented. Always consult your physician or pharmacist before taking medications concurrently. CLICK HERE for more information on drug interactions.




 P2Y12 INHIBITORS + ANTICOAGULANTS



 CLOPIDOGREL AND CYP2C19

Overview
Clopidogrel and PPIs

Clopidogrel and Poor metabolizers




 LONG TERM SAFETY



 DOSING



 GENERIC

Generic:

Possible generic:

DRUG PATENT EXPIRES
Prasugrel (Effient®) APR 2017
Ticagrelor (Brilinta®) JUL 2018

NOTE: Drug companies typically file multiple patents on their drugs in order to protect them from competition. The patent expiration listed here is the date that the earliest patent on the drug expires (accounting for pediatric exclusivity). Because drug companies use numerous techniques to extend the life of their patents, it does not necessarily mean a generic will become available around this date.


 COST SAVINGS OPPORTUNITIES



 CLASS DIFFERENCES



 RECENT STUDIES



 BIBLIOGRAPHY

    What is PMID?    PI = Manufacturer's Package Insert